Corporate

July 10, 2014

Vedolizumab (ENTYVIO): Claim Submission Instructions

Vedolizumab (ENTYVIO) is an integrin receptor antagonist indicated for adult patients with moderate to severe active ulcerative colitis and for adult patients with moderate to severe active Crohn's Disease.

Claims for Vedolizumab must include:

  • HCPCS code J3590
  • The name of the drug, NDC number, and exact dosage administered
    • Electronic claims: Loop 2400, NTE02, or SV101-7 field
    • Paper claims: item 19
  • Units field = 1, based on the 300mg single dose vial

Two Vantage Way, Nashville, TN 37228 © CGS Administrators, LLC. All Rights Reserved